Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250024/S001

Trilogy Transcatheter Heart Valve System

JenaValve Technology, Inc. · Decision date May 18, 2026

FDA DECISIONP250024/S001

What did the FDA approve?

FDA records P250024/S001 as a supplement to PMA P250024, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated May 18, 2026.

FDA approval order statement

approval for the protocol for the Continued Follow-up of the Premarket Cohort post-approval study (PAS)
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Cardiovascular
Decision date
May 18, 2026
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P250024/S001
Regulatory pathway
PMA supplement
Product code
NPT
Decision code
APPR
Decision date
May 18, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Aortic valve, prosthesis, percutaneously delivered.

Product code
NPT
FDA device class
3

For the original device and its historical approval scope, see PMA P250024. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250024 · Original PMA

    Trilogy Transcatheter Heart Valve System

  2. P250024/S001 received

    Application receipt date recorded by FDA.

  3. P250024/S002 · Related supplement

    Trilogy Transcatheter Heart Valve System

  4. P250024/S001 · FDA decision

    Normal 180 Day Track No User Fee

  5. P250024/S003 · Related supplement

    Trilogy Transcatheter Heart Valve System

  6. P250024/S006 · Related supplement

    Trilogy Transcatheter Heart Valve System

  7. P250024/S005 · Related supplement

    Trilogy Transcatheter Heart Valve System

Timeline entries are records held by MedtechLedger for P250024. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250024

Product / regulatory recordCompanyPathwayDecision dateSource
JenaValve Technology, Inc.PMA approvalMar 17, 2026FDA
JenaValve Technology, Inc.PMA supplementMay 18, 2026FDA
JenaValve Technology, Inc.PMA supplementJul 9, 2026FDA
JenaValve Technology, Inc.PMA supplementOct 7, 2026FDA
JenaValve Technology, Inc.PMA supplementOct 13, 2026FDA

Explore the linked device profile

Other records with product code NPT

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

JenaValve Technology, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
4 Cromwell, Irvine, CA, 92618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records